65 results about "Technetium-99m" patented technology

A process for producing technetium-99m from a molybdenum-100 metal powder, comprising the steps of:

• • (i) irradiating in a substantially oxygen-free environment, a hardened sintered target plate coated with a Mo-100 metal, with protons produced by a cyclotron;
  • (ii) dissolving molybdenum ions and technetium ions from the irradiated target plate with an H₂O₂ solution to form an oxide solution;
  • (iv) raising the pH of the oxide solution to about 14;
  • (v) flowing the pH-adjusted oxide solution through a resin column to immobilize K[TcO₄] ions thereon and to elute K₂[MoO₄] ions therefrom;
  • (vi) eluting the bound K[TcO₄] ions from the resin column;
  • (vii) flowing the eluted K[TcO₄] ions through an alumina column to immobilize K[TcO₄] ions thereon;
  • (viii) washing the immobilized K[TcO₄] ions with water;
  • (ix) eluting the immobilized K[TcO₄] ions with a saline solution; and
  • (x) recovering the eluted Na[TcO₄] ions.

The invention relates to a bone-seeking 99mTc-IPrDP coordination compound, belonging to the fields of radiopharmaceuticals and nuclear medicine. The structural formula of the bone-seeking 99mTc-IPrDP coordination compound is shown in the specification. The preparation method of the coordination compound is as follows: mixing ligand IPrDP, reducing agent, pH buffer solution and pertechnetic acid (99mTcO<4->) solution to react to obtain an IPrDP coordination compound labeled by technetium-99m. The 99mTc-IPrDP coordination compound is used for nuclear medical diagnostic imaging. Through comparison, the product provided by the invention has the advantages of good product specificity, high bone/tissue intake (Am, bone) (% ID/g) and (Am, bone/Am, blood) and good tissue clearance rate, thus being expected to become novel bone imaging agent.

The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors include technetium and rhenium complexes. The high tumor uptake and significant tumor/nontumor ratios of the technetium complexes of the invention indicate that such small technetium-99m-based molecular probes can be developed as in-vivo diagnostic agents for melanoma and its metastases. In yet another embodiment, the invention relates to methods of treatment of tumors using a radiolabeled metal complex as a radiopharmaceutical agent to treat the tumor.

The invention is directed to modified minigastrin analogs. It further relates to labeling such modified minigastrin analogs with metallic radionuclides. The invention further relates to methods for making such novel modified minigastrin analogs, their labeling with metallic radionuclides and their use in oncology applications as in the targeted diagnostic imaging and staging of CCK-2/gastrin-R-positive neoplasms in man with SPECT (technetium-99m), or PET (technetium-94m), or eventually in targeted radionuclide therapy (rhenium-188).

A generator that allows for a non-fission based method of producing and recovering ^99mTc from neutron-irradiated molybdenum. This generator system is based on the isolation of ^99mTc, as the decay product from a source of ⁹⁹Mo labelled molybdenum carbonyl Mo(CO)₆ through a distillation process. The ^99mTc obtained from this distillation is produced with high efficiency and purity in a solvent-free form, which can then be dissolved in water or other solvents to produce a solution at the required specific activity and concentration, as reasonably determined by the operator.

Diphosphate complex of ZL phosphonic acid with radioactive technetium-99m mark and its production are disclosed. Diphosphate of ZL phosphonic acid is 2-(imidazole-1-radical)-1-hydroxyl ethane-1, 1-di-(2-ethylhexyl)phosphoric acid ZL phosphonic acid , ZL), 2-(2-methyl imidazole-1-radical)-1-hydroxyl ethane-1, and 1-diphosphate(MZL). It is carried out by combining diphosphate(ZL or MZL) of ligand ZL phosphonic acid and reducer with pH buffering agent to be medicine pack, adding pertechnetate(99mTcO4-) solution into medicine pack, reacting, and obtaining diphosphate complex 99mTc-ZL or 99mTc-MZL of ZL phosphonic acid with radioactive technetium-99m mark. It can be used for nuclear medical diagnostic image or treat rheumatoid disease and tumor.

This invention relates to compositions that are radiolabeled scintigraphic imaging agents, comprising a polybasic compound covalently linked to a radiolabel binding moiety and the composition further comprising a polysulfated glycan. The invention also provides methods for producing and using such compositions. Specifically, the invention relates to compositions comprised of technetium-99m (Tc-99m) labeled scintigraphic imaging agents comprising a polybasic compound having at least 5 chemical functionalities that are basic at physiological pH and a radiolabel-binding moiety, the composition further comprising a polysulfated glycan, the composition being capable of accumulating at inflammatory sites in vivo. Methods and kits for making such compositions, and methods for using such compositions to image sites of infection and inflammation in a mammalian body, are also provided.

The invention relates to a technetium-99m labeled propyl zoledronic acid composition and a preparation method thereof, belonging to the fields of radiopharmaceuticals and nuclear medicines. The propyl zoledronic acid composition is technetium-99m labeled 1-hydroxy-2-(propyl-1H-iminazole-1-base)-ethane-1, 1-diphosphic acid (99Tcm-PIDP). The preparation method of the composition comprises the step of reacting the ligand PIDP, a reducing agent SnCI2.2H2O and a pH buffer solution with a pertechnetic acid (99TcmO4-) solution to obtain the technetium-99m labeled PIDP composition. The 99Tcm-PIDP is used for diagnostic imaging. The product of the 99Tcm-PIDP has higher bone tissue intake (Am, bone) (% ID/g) and (Am, bone/Am, blood) than a document value and rapid tissue removal speed, which shows that the product has the potential of being used as a bone developing agent.

The invention discloses a technetium-99m-labeled graphene oxide nanoparticle and a preparation method thereof. The preparation method comprises the steps as follows: (1) enabling an alkynyl-modified ligand compound and azido-modified graphene oxide to have a Click reaction, and purifying coarse products to obtain a reactant A, wherein the ligand compound is a macrocyclic ligand compound; (2) evenly mixing the reactant A, a hydrochloric acid of stannous chloride and high-technetium acid radial ions in a solvent to obtain mixed liquor, adjusting the pH of the mixed liquor to 6.0-7.5, and performing a reduction coordination reaction to obtain the nanoparticle. The preparation method is high in reaction selectivity, mild in condition, simple to operate and higher in labeling yield. The technetium-99m-labeled graphene oxide nanoparticle is very good in biocompatibility and better in water solubility, can be used for studying the real-time distribution condition of graphene oxide in the cell level and the small animal level and provides more basic information for the application of the graphene oxide to organisms later.

The invention provides a 99mTc(III) complex containing arylboronic acid. A molecular formula of the 99mTc(III) complex is 99mTcC1(CDO)(CDOH)2B(F-R), wherein F is furyl and R is methoxyl, formaldehyde or hydroxymethyl. The compound has the characteristics of simple preparation, low price, high labeling rate, high radiochemical purity, high target to non-target ratio, high heart uptake value, long residence time and the like, and can be used as a novel technetium-99m labeled myocardial perfusion imaging agent which is applied to the technical fields of radiopharmaceutical chemistry and clinical nuclear medicines.

A isocyanide complex for technetium-99m mark, wherein Tc(I) is arranged to be the central core, the coordinated isocyanide ligand is represented by formula CN-R, wherein R is C6-10 cycloalkyl substituted or unsubstituted by any of 1-4 same or different C1-4 alkyl or alkoxy, the complex is prepared by wet method or freeze-drying method, it can be used as blood pool imaging agent with the advantages of simple preparing process, low price and high ratio of target / non-target.

The invention discloses a technetium-99m-marked poly N-vinyl benzyl-D-lactose amide composition. By using 99mTc as a central core, using polymer-poly N-vinyl benzyl-D-lactose amide-N-vinyl benzyl-6-hydrazino pyridine-3-formamide containing 6-hydrazino pyridine-3-formamide groups and galactose groups as a ligand, adopting one of N-tris hydroxymethyl-methylglycine, N,N-2-hydroxyethyl glycine and N-2-hydroxyethyl ethylene diaminetriacetic acid as a common ligand and adopting one of tris(3-sulfonatophenyl) phosphine hydrate or tris(3-sulfonatophenyl) phosphine sodium salt as a synergetic ligand, the technetium-99m-marked poly N-vinyl benzyl-D-lactose amide composition is prepared through the steps of mixing, reduction, reaction, purification and the like. The composition has the advantages of good chemical stability and biological performance, high specific activity, high liver uptake value and target to non-target ratio, simple preparation and low operating cost and can be used for preparing novel liver receptor developers applied in the technical fields of radiopharmaceutical chemistry and clinical nuclear medicine.

The invention relates to a sigma 1 receptor bound tricarbonyl cyclopentadiene ligand compound, and a preparation method and an application of the ligand compound. A structural general formula of the ligand compound is shown as (I) as shown in the specification, wherein n is equal to 3 or 5, and M is rhenium or technetium-99m. The tricarbonyl cyclopentadiene ligand compound has high affinity and moderate selectivity to a sigma 1 receptor, and is an initially found sigma 1 receptor ligand with nanomolar affinity. After labeled by technetium-99m, the ligand compound has a higher labeling rate, high radiochemical purity and excellent biological properties, is applicable to an SPECT (single photon emission computed tomography) tracer, breaks through the low brain uptake bottleneck of a 99 mTc labeled sigma 1 receptor tracer, and has wide clinical application prospects.

The invention discloses a technetium-99m labeled dimercaptopropanol amido new lactose albumin complex, a preparation method and application thereof; radioactive pertechnetate (TcO4) is synthesized with dimercaptopropanol amido new lactose albumin into a ligand (DMP-NGA); and under the presence of reducing agent and protective agent, the radioactive technetium-99m labeled dimercaptopropanol amido new lactose albumin complex is prepared by reaction. The complex has good chemical stability and biological property, high initial uptake value and target and chemical purity, simple preparation and low use cost, and can be used in radiopharmaceuticals and clinical nuclear medicine technology field as a novel liver imaging agent.

The present invention relates generally to a system and method for producing Technetium-99m. More specifically, the present invention relates to a novel method and device for modifying commercially-available, widely-used low energy positron emission tomography (PET) cyclotrons in order to produce Technetium-99m in a more efficient, less expensive manner that previously known.

Systems and methods for separation or isolation of technetium radioisotopes from aqueous solutions of radioactive or non-radioactive molybdate salts using a polyalkyl glycol-based cross-linked polyether polymer. Some embodiments can be used for the effective purification of radio-active technetium-99m produced from low specific activity ⁹⁹Mo.

The invention relates to a technetium-99m-labeled higher fatty acid derivative and in particular relates to a technetium-99m-labeled long-chain fatty acid metabolism product. According to the long-chain fatty acid metabolism product, sulfonyl and a thiophene ring are introduced into long-chain fatty acids, so that the molecular lipid solubility is reduced, the myocardial uptake of the medicament is increased, and the retention time of the medicament in the myocardium is prolonged. The experiment proves that according to the designed higher fatty acid compounds, the myocardial uptake is improved, and the retention time of the medicament is prolonged.

The present invention relates to tricarbonyl technetium-99m or rhenium-188 labeled cyclic RGD derivatives, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment (radiotherapy) of angiogenesis-related diseases. The tricarbonyl technetium-99m or rhenium-188 labeled cyclic RGD derivatives of the present invention has a high subnanomolar affinity to integrin α_vβ₃ (also called as a vitronectin receptor) that is activated in an angiogenic action induced by a tumor, reflects a high tumor image of the tricatvonyl technetium-99m labeled cyclic RGD derivative after initial intake in an animal in which cancer cells are transplanted, and acts exclusively upon cancer cells having selectively activated integrin α_vβ₃ because of a substantially low intake into the liver and intestines, compared to existing known radioactive isotope labeled cyclic RGD derivatives. These results show that the rhenium-188 labeled derivative, a therapeutic nuclide using the same precursor as used in the technetium-99m labeling, effectively inhibits the growth of a tumor and demonstrates therapeutic efficacy when administered via tail vein injection to an animal model bearing tumor, compared to a case where only saline has been injected, thereby making it useful as a medicine for the diagnosis or treatment of angiogenesis-related diseases.

Disclosed herein are a method of preparing a technetium-99m-labeled iron oxide (Fe₂O₃) nanoparticle and a diagnostic imaging or therapeutic agent for cancer diseases comprising the nanoparticle. The ^99mTc-iron oxide nanoparticle is prepared using an acidic solution or a borohydride anion exchange resin as a reducing agent, and thus, is easy to inject into the body, and its biodistribution and excretion from the body is easily predicted. The ^99mTc-iron oxide nanoparticle eliminates cancerous tissues as well as enabling non-invasive real-time imaging for obtaining anatomical information about cancerous tissues and tissue functions without the need for surgery. Also, the iron oxide nanoparticle may be useful as an imaging agent for various diseases including tumors, contagious diseases and genetic defects.